Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies.

Reem AlmutairyMansoor Ahmed Khan Alaa ShahbarMohammed AseeriMajed AlshamraniHassan AlmarhabiDoaa Naeem

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)

The use of voriconazole instead of posaconazole for 130 chemo cycles would save $166,584.6. Posaconazole and voriconazole have comparable efficacy and safety in preventing IFD in AML and MDS patients receiving chemotherapy. However, posaconazole is more costly than voriconazole.

Keyphrases

locally advanced
acute myeloid leukemia
photodynamic therapy
candida albicans
radiation therapy
cancer therapy
combination therapy
rectal cancer